RNS Number : 6023K
Immupharma PLC
22 December 2022
 

                                                                                                                                                                 22 December 2022

 

ImmuPharma PLC

("ImmuPharma" or the "Company")

 

                      Grant of Share Options

 

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the grant of share options as follows.

 

The Remuneration Committee (comprising the Non Executive Directors) has determined to award  Share Options to the Executive Directors with exercise prices and conditions which reflect the underlying objective of restoring and enhancing shareholder value as follows:

 

Tim McCarthy                    1,800,000 share options (exercise price £0.05)

Tim McCarthy                    1,800,000 share options (exercise price £0.11)

Tim Franklin                       1,575,000 share options (exercise price £0.05)

Tim Franklin                       1,575,000 share options (exercice price £0.11)

 

Vesting & Performance conditions:

 

·    3 year vesting period; and

·    1st patient dosed in the next P140 (Lupuzor™) clinical trial.

 

ENDS

 

For further information please contact:

 

ImmuPharma PLC (www.immupharma.com)

Tim McCarthy, Chief Executive Officer

Lisa Baderoon, Head of Investor Relations

+44 (0) 207 206 2650

 

+ 44 (0) 7721 413496

 



 

SPARK Advisory Partners Limited (NOMAD)

Neil Baldwin

 

Stanford Capital Partners (Joint Broker)

Patrick Claridge, John Howes, Bob Pountney

 

SI Capital (Joint Broker)

Nick Emerson

 

 

 

+44 (0) 203 368 3550

 

 

+44 (0) 203 650 3650

 

 

+44 (0) 1483 413500

 

 




 

Notes to Editors

 

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, Lupuzor™, is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

 

For additional information about ImmuPharma please visit www.immupharma.co.uk

 

ImmuPharma's LEI (Legal Entity Identifier) code : 213800VZKGHXC7VUS895.

 


Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them.

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

Name

Tim McCarthy

2

Reason for the notification

a)

Position/status

Chairman and Chief Executive Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

ImmuPharma PLC

b)

LEI

213800VZKGHXC7VUS895

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of 1p each

 

 

ISIN: GB0033711010

b)

Nature of the transaction

Grant of share options over new Ordinary Shares

c)

 

Price(s) and volume(s)

 

Exercise Price

Volume

5 pence

1,800,000



11 pence

1,800,000

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

N/A

e)

Date of the transaction

22 December 2022

f)

Place of the transaction

n/a

 

 

 

 

 

1

 

Details of the person discharging managerial responsibilities / person closely associated

 

a)

Name

Tim Franklin

2

Reason for the notification

a)

Position/status

Chief Operating Officer

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

ImmuPharma PLC

b)

LEI

213800VZKGHXC7VUS895

4

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

 

Description of the financial instrument, type of instrument

 

Identification code

 

Ordinary Shares of 1p each

 

 

ISIN: GB0033711010

b)

Nature of the transaction

Grant of share options over new Ordinary Shares

c)

 

Price(s) and volume(s)

 

Exercise Price

Volume

5 pence

1,575,000



11 pence

1,575,000

d)

 

Aggregated information

 

- Aggregated volume

 

- Price

 

N/A

e)

Date of the transaction

22 December 2022

f)

Place of the transaction

n/a

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHUUOBRUBUUURA